InterCure regains Nasdaq minimum bid compliance

InterCure Ltd. (INCR) announced that Nasdaq’s Listing Qualifications Department confirmed the company has regained compliance with the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement.

Rhea-AI Filing Summary

InterCure Ltd. (INCR) announced that Nasdaq’s Listing Qualifications Department confirmed the company has regained compliance with the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement. Nasdaq determined that for the 10 consecutive business days from August 24, 2026 through September 4, 2026, InterCure’s ordinary shares closed at $1.00 per share or greater, closing a prior delisting proceeding.

The company had earlier received a notification on February 25, 2026 that its shares were below $1.00 for 30 consecutive business days and a subsequent delisting notice on September 1, 2026 after not regaining compliance within a 180‑day period ending August 24, 2026. InterCure describes itself as a leading and profitable cannabis company outside North America, operating through its wholly owned subsidiary Canndoc in Israel.

Positive

• Nasdaq compliance restored: InterCure regained compliance with Nasdaq’s minimum bid price rule after its shares traded at or above $1.00 for 10 consecutive business days, and Nasdaq has closed the matter, removing an immediate delisting risk.

Negative

• Recent delisting risk: InterCure previously failed to meet Nasdaq’s $1.00 minimum bid price for 30 consecutive business days and received a delisting notice on September 1, 2026, highlighting recent vulnerability in its share price.

Key Figures

Minimum Bid Price Threshold: $1.00 per share Non-compliance period: 30 business days Compliance grace period: 180 calendar days +3 more

6 metrics

Minimum Bid Price Threshold $1.00 per share Nasdaq Listing Rule 5450(a)(1) requirement for continued listing

Non-compliance period 30 business days Consecutive days InterCure’s closing bid was below $1.00 before February 25, 2026 notice

Compliance grace period 180 calendar days Period ending August 24, 2026 granted to regain minimum bid price compliance

Compliance trading window 10 business days August 24, 2026 through September 4, 2026 with closing bid at or above $1.00

Delisting notice date September 1, 2026 Nasdaq stated InterCure’s ordinary shares were subject to delisting

Compliance confirmation date September 8, 2026 Nasdaq confirmed InterCure regained compliance and closed the matter

Key Terms

Minimum Bid Price Requirement, Nasdaq Global Market, Listing Qualifications Department, Good Manufacturing Practices (GMP), +1 more

5 terms

Minimum Bid Price Requirement regulatory

"regained compliance with the minimum bid price requirement set forth"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Global Market market

"its ordinary shares were subject to delisting from The Nasdaq Global Market"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

Listing Qualifications Department regulatory

"received written confirmation from the Listing Qualifications Department"

A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.

Good Manufacturing Practices (GMP) medical

"one of the first to offer Good Manufacturing Practices (GMP) certified"

Good manufacturing practices (GMP) are the set of rules and controls that ensure drugs, medical devices, and related products are made cleanly, consistently, and to the quality claimed on the label. For investors, GMP matters because meeting these standards reduces the chance of product recalls, production shutdowns, fines, or lost approvals—similar to a restaurant that follows strict recipes and hygiene to avoid food poisoning and keep customers coming back.

seed-to-sale technical

"a high-margin vertically integrated “seed-to-sale” model"

Seed-to-sale describes a tracking system that follows a product from initial planting through processing, distribution and final retail sale, ensuring every step is recorded and traceable. For investors it matters because it demonstrates regulatory compliance, reduces the chance of missing inventory or legal problems, and gives clearer visibility into production, costs and potential revenue—think of it as a permanent receipt that follows a product through its entire life cycle.

FAQ

What did InterCure Ltd. (INCR) announce in this Form 6-K?

InterCure announced that Nasdaq confirmed the company has regained compliance with the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement, and that the prior delisting matter concerning its ordinary shares is now closed.

How did InterCure (INCR) regain compliance with Nasdaq’s minimum bid price rule?

Nasdaq notified InterCure that for the 10 consecutive business days from August 24, 2026 through September 4, 2026, the closing bid price of its ordinary shares was $1.00 per share or greater, satisfying the Minimum Bid Price Requirement.

Why was InterCure (INCR) previously out of compliance with Nasdaq’s rules?

On February 25, 2026, InterCure received notice that the closing bid price of its ordinary shares had been below $1.00 for 30 consecutive business days, meaning it was not in compliance with Nasdaq’s Minimum Bid Price Requirement.

What was the compliance period Nasdaq gave InterCure (INCR) to fix its bid price?

Under Nasdaq Listing Rule 5810(c)(3)(A), InterCure received a 180‑calendar day compliance period, up to August 24, 2026, to regain compliance with the Minimum Bid Price Requirement after the February 25, 2026 notice.

Did InterCure (INCR) receive a delisting notice from Nasdaq?

Yes. On September 1, 2026, InterCure received a delisting notice stating its ordinary shares were subject to delisting from The Nasdaq Global Market because it had not regained compliance within the initial 180‑day period.

What business does InterCure (INCR) operate?

InterCure, operating as Canndoc, describes itself as a leading and profitable cannabis company outside North America. Its subsidiary Canndoc is Israel’s largest licensed cannabis producer, offering GMP-certified, pharmaceutical‑grade medical cannabis products via a vertically integrated seed‑to‑sale model.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:13 PM Accepted by SEC EDGAR 09/08/2026 - 04:13 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2026

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 8, 2026, InterCure Ltd. (the “Registrant”) issued a press release, titled “InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement”. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

Exhibit No.
99.1		Press Release issued by InterCure Ltd. on September 8, 2026, titled “InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: September 8, 2026	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer

Exhibit 99.1

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK and HERZLIYA, Israel, September 8, 2026 (GLOBE NEWSWIRE) - InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) announced today that it received written confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The confirmation follows a written notification received by the Company from Nasdaq on September 1, 2026, indicating that the Company’s ordinary shares were subject to delisting from The Nasdaq Global Market (the “Delisting Notice”).

As previously disclosed, on February 25, 2026, the Company received notification from Nasdaq that the closing bid price of its ordinary shares had been below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day compliance period, or until August 24, 2026, to regain compliance.

On September 1, 2026, the Company received the Delisting Notice stating that the Company had not regained compliance with the Minimum Bid Price Requirement within the applicable compliance period and that its ordinary shares were therefore subject to delisting from The Nasdaq Global Market. Subsequently, on September 8, 2026, Nasdaq notified the Company that, for the 10 consecutive business days from August 24, 2026 through September 4, 2026, the closing bid price of the Company’s ordinary shares was $1.00 per share or greater.

Accordingly, Nasdaq determined that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1), and that the matter is now closed.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Company Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

amos@intercure.co

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 8.4 KB
• EX-99 GRAPHIC 23.5 KB